Apalutamide treatment of locally advanced prostate cancer Case report

Article Sidebar

PDF PDF (Język Polski)


Published: Mar 31, 2023
DOI: https://doi.org/10.24292/01.OR.131315323
Keywords:
prostate cancer, castration resistance, hormonotherapy, apalutamide

Main Article Content

Maria Palasik
Provincial Center of Oncology in Gdansk

Abstract

Prostate cancer is most commonly diagnosed cancer in men. The choice of treatment method depends on many factors: the patient’s age, other patient’s diseases, psychophysical status and expected survival time. Hormonotherapy plays very important role in patients with no possible radical treatment. New therapies apply in patients with castration-resistant metastatic prostate cancer. First registered drug in patients with biochemical progression without metastases is apalutamide.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Palasik M. Apalutamide treatment of locally advanced prostate cancer. OncoReview [Internet]. 2023Mar.31 [cited 2024Nov.22];13(1(49):31-2. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/2792
Issue
Vol 13 No 1(49) (2023)
Section
SUPPORTIVE CARE IN ONCOLOGY

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Krajowy Rejestr Nowotworów 2021 r.
2. Smith MR, Saad F, Chowdhury S et al. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2021; 79(1): 150-8.